

CURRICULUM VITAE

ARNOLD I. MILLER, D.O., MBA, FACOI

FELLOWSHIPS:

Hematology
Martin Place Hospitals
Madison Heights, MI - July '75 to June '76

Oncology
Wayne State University
Detroit, MI – June '76 to June '77

BOARD CERTIFICATIONS:

American Osteopathic Board of Internal Medicine

1. Internal Medicine
2. Medical Oncology
3. Hematology

LICENSURE:

Florida

PUBLICATIONS:

“The Mallory-Weiss Syndrome: in the Michigan Osteopathic Journal, Vol. 34, November 1974.

“Ftotafor in Advanced Colorectal Carcinoma in Patients Previously Treated with Fluorinated Pyrimadines” in the Cancer Treatment Reports, 1977.

INTERESTS:

Horseback riding with his lovely wife Candy
Fly fishing

EDUCATION:

HIGH SCHOOL: Weequahic High School
Newark, NJ
DEGREE: Diploma – June 1964

UNIVERSITY: Boston University
Boston, MA
DEGREE: B.A., Psychology – June 1968

MEDICAL SCHOOL: Kansas City College of Osteopathic
Medicine and Surgery

HONORS: Pi Sigma Alpha (Osteopathic Honor Society)
“Who’s Who in American Colleges and
Universities”, 1972

DEGREES: D.O. – June 1972

INTERNSHIP: Green Cross-General Hospital
Cuyahoga Falls, OH – June 1972 to June 1973

RESIDENCY: Internal Medicine
Zeiger-Botsford Hospitals
Farmington, MI – July 1973 to June 1975

**POST GRADUATE
STUDIES:** Physician MBA
University of South Florida
1995 – 1997

MEDICAL PRACTICE EXPERIENCE:

Arnold I. Miller, D.O.
Private Practice
Portland, Oregon 1977 – 1983

Osceola Cancer Center
1300 W. Oak Street
Kissimmee, FL 34741 1983 – Present

PROFESSIONAL ACTIVITIES:

1. Director of Medical Education, Eastmoreland General Hospital
Portland, OR, May 1982 – July 1983.
2. Member, Board of Directors, College of Osteopathic Medicine of the Pacific,
Pomona, CA 1978 – 1981.
3. Served on various committees of the American Cancer Society.
4. Member, Teaching Staff, Emmanuel Hospital, Portland, OR.
5. Chairman, various committees at Eastmoreland General Hospital, Portland, OR.
Including Long Range Planning, Bylaws, Administrative Search Committee, Locations,
Intern Training, Tumor Board / Cancer Committee and Pharmacy & Therapeutics.
6. Vice-chairman, Department of Internal Medicine, Eastmoreland General Hospital,
Portland, OR 1979 – 1983.
7. Guest lecturer at various community organizations.
8. Adjunct Clinical Faculty at Comp and Instructor of a yearly 18 hour course in
Hematology, College of Osteopathic Medicine of the Pacific, Pomona, CA, 1980 – 1983.
9. Past Chairman of the Political Action Committee, Oregon Osteopathic Association.
10. Program Coordinator, Oregon/Washington Conference, Ashland, OR – 1979.
11. Liaison Physician, Oncology Unit, Eastmoreland General Hospital, Portland, OR.
12. Member, Board of Directors, American Cancer Society, West Osceola (Florida) Unit.
13. Medical Advisor, American Cancer Society, West Osceola (Florida) Unit.
14. Member, Board of Directors, Hospice of Osceola County, Florida.
15. Member, The Editorial Review Board for Journal of Managed Care Medicine.
16. Member, Physicians Advisory Board, Clinical Pharmacy Services.
17. Chairman, Physicians Advisory Board, Humana Care Plus.
18. Member, Physicians Advisory Board, Home Med Services.
19. Assistant Medical Director, Humana Care Plus, Osceola County.

20. Lecturer on various oncology topics including breast cancer, colon cancer, immunotherapy and pain control. Lectured at OCOI Spring Conference, February 28, 1986 and FOMA District XI, December 7, 1986.
21. Speakers Bureau for DuPont Pharmaceutical and Purdue Frederick.
22. Chairman, Quality Assurance, Medical Records and Utilization Review Committees, Osceola Regional Hospital, Kissimmee, Fl.
23. Consultant, Sub-specialty of Hematology, American College of Osteopathic Internists.
24. Chairman, Department of Internal Medicine, Osceola Regional Hospital, Kissimmee, FL 1987 – 1989.
25. Named by Florida Governor, Bob Martinez to the C-CRAB, 1990 – 1993.
26. President, Medical Staff, Osceola Regional Hospital, Kissimmee, FL 1991 – 1992.
27. Associate Medical Director, Hospice of Central Florida, 1991.
28. Member, Board of Trustees, Osceola Regional Hospital, Kissimmee, FL 1992 – 1994.
29. Physician Advisor, Osceola Regional Hospital, Kissimmee, FL, April 1994 – 1996.
30. Chairman, Board of Directors, Physicians Health Network (Columbia Park), August 1994 – 1996.

RESEARCH EXPERIENCE:

Investigator, Southwestern Oncology Group (SWOG), through Eastmoreland General Hospital, Portland, OR (past).

Investigator, Cancer and Leukemia Group B (CALGB) and National Surgical Adjuvant Bowel Project (NSABP), Walt Disney Memorial Cancer Institute, Florida Hospital, Orlando, FL in cooperation with Duke University, Orlando, FL 1993.

Investigator, Radiation Therapy Oncology Group (RTOG), Osceola Regional Hospital, Kissimmee, FL., in cooperation with Johns Hopkins Hospital, 1993.

Sub-Investigator, Faulding Pharmaceutical, Inc./ Harris Laboratories, Protocol CD-14556, “A randomized, double-blind, Parallel Group Study Comparing the Efficacy and Safety of Kapanol to MS Contin in the Management of Patients with Moderate to Severe Cancer Pain”, July 1993 to March 1994.

Sub-Investigator, Faulding Pharmaceuticals, Inc., /Harris Laboratories, Protocol CDD-14785, “A long term Safety Evaluation of Kapanol and MS Contin in Patients with Moderate to Severe Cancer Pain”, July 1993 to October 1994.

Principal Investigator, Amgen, Inc., Research Protocol PR 93-27-003, “Procrit (Epoetin Alfa): Phase IV Clinical Evaluation in Anemic Patients Receiving Chemotherapy”, September 1993 to May 1994.

Sub-Investigator, ZENECA Pharmaceuticals Group, Protocol 1033IL/004, “A Randomized, Multi-center, Efficacy and Safety Study to Evaluate Arimidex 1 and 10 mg double-blind, Compared to Open Label Megace in Post-menopausal Women with Advanced Breast Cancer”, February 1994.

Sub-Investigator, The Purdue Frederick Company, Protocol OC93-0202, “double-blind, Randomized, Two-Period Crossover Efficacy Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of Immediate-Release Oxycodone and Controlled-Release Oxycodone in Cancer Patients with Pain”, March 1994 to January 1995.

Sub-Investigator, The Purdue Frederick Company, Protocol OC92-1101, “Open-Label Clinical Use Study of Controlled-Release Oxycodone Tablets Administered Orally every 12 hours for the Management of Pain”, March 1994.

Sub-investigator, Pharmacia Inc., Protocol 120002, “Efficacy Trial of FCE 24304 (Exemestane) in the Treatment of Postmenopausal patients with Metastatic Breast Cancer Failing Tamoxifen”, June 1994.

Sub-Investigator, Pharmacia Inc., Protocol 120003, “Anti-tumor Efficacy Trial of FCE 24304 (Exemestane) as Third Line Hormonal Therapy in the Treatment of Postmenopausal Women with Metastatic Breast Cancer Refractory to Tamoxifen and Megace, June 1994.

Sub-investigator, Pharmacia Inc., Protocol 129004, “Anti-tumor Efficacy Trial of FCE 24517 (Tallimustine) in the Treatment of Adult Patients with Renal Cell Carcinoma”, September 1994 to August 1995.

Sub-Investigator, Pharmacia Inc., Protocol 12005, Anti-tumor Efficacy Trial of FCE 24517 (Tallimustine) in the Treatment of Adult Patients with Adenocarcinoma of the Stomach or Gastro-Esophageal Junction”, September 1994 to August 1995.

Sub-Investigator, Pharmacia Inc., Protocol 129006, “Anti-tumor Efficacy Trial of FCE 24517 (Tallimustine) in the Treatment of Adult Patients with Carcinoma of the Pancreas”, September 1994 to August 1995.

Sub-Investigator, Roberts Pharmaceutical Corp., Protocol 13,970-301B, “An open Protocol for the use of Agrelin (Anagrelide) for Patients with Thrombocytopenia”, September 1994.

Sub-Investigator, The Purdue Frederick Company, Protocol OC92-1001, “double-blind, Randomized, Q12H, Multiple-Dose, Parallel Group Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of Controlled-Release Oxycodone (Oxycontin) and MS Contin Tablets in Patients with Chronic Cancer-Related Pain”, November 1994 to present.

Sub-Investigator, Roberts Pharmaceutical, Protocol 38,594-301B, “An open Controlled Study of Deslorelin for the Treatment of Stage D2 Prostate Cancer”, March 1995 to May 1995.

Principal Investigator, Phone Poulenc Rorer Protocol 60180X-204A, “A Randomized double blind Parallel Group Single Dose Comparative Study of RO60180 (0.5 mg and 7.5 mg) and Morphine Sulphate (20 mg), in patients with Cancer Pain”, April 1995 to August 1995.

Sub-Investigator, SoloPak Pharmaceuticals Inc. Protocol SP-MM-01, “A Randomized, double-blind, Multi-center Study of Low-Dose Gallium Nitrate for Treatment of Bone Involvement Due to Multiple Myeloma’, August 1995.

Sub-Investigator, Pharmacia Inc. Protocol 95-OEXE-022, “Anti-tumor Efficacy of Exemestane in Postmenopausal Women with Metastatic Breast Cancer Failing Tamoxifen and Megace”, September 1995.

Sub-Investigator, Genetech, Inc., Protocol H2251n, “Clinical Outcomes in Patients with HER2 Gene-Amplified Metastatic Breast Cancer Treated with First-Line Herceptin in Combination with Taxane: phase IV, Prospective, Community-Based Study”, July 2001 to present.

Principal Investigator, Novartis Pharmaceuticals Corp., Protocol CZOL446EUS16, “A Prospective, Multicenter, Open-Label Clinical Evaluation of the Effect of I.V. Zometa 4mg. On Pain, quality of Life and Time in Infusion Chair in Breast Cancer, Multiple Myeloma and Prostate Cancer Patients with Cancer-Related Bone Lesions”, October 2001 to September 2002

Principal Investigator, Pharmacia, Inc., Protocol 378-ONC-0030-184, “Phase III Study of Epirubicin / Cyclophosphamide Followed by Taxane (Sequential Chemotherapy) versus Epirubicin / Taxane (Concurrent Chemotherapy) as Adjuvant Treatment for Operable, Node-Positive Breast Cancer”, October 2001 to present.

Principle Investigator, Amgen, Protocol NESP 20000220, “An Open-Label, Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin alfa (NESP)”, October 2001 to present.

Principle Investigator, Roche Pharmaceuticals, Protocol XEL-154, “A Pilot Trial of Two Different Doses of Capecitabine (XELODA) in patients with Advanced and/or Metastatic Breast Cancer”< November 2001 to present.

Principal Investigator, Amgen, Protocol NESP 20000219, “A Randomized, Open-Label, Comparatives Study to estimate the Effect of Darbepoetin alfa on Hospital Days, Economic Outcomes and Health-Related quality of Life in Subjects with Nonmeyloid Malignancies and Anemia of Cancer”, November 2002 to present.